Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA FOSL1
- Development stage
- Preclinical
- Lead developer
- Xavier University of Louisiana
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
siRNA FOSL1 is a small interfering RNA (siRNA) designed to silence the expression of the FOSL1 (FOS-like 1) gene, also known as Fra-1. FOSL1 is a member of the AP-1 transcription factor family and plays a critical role in regulating the stemness, proliferation, and survival of glioma stem cells (GSCs). Research indicates that FOSL1 expression is positively regulated by TRPM7-mediated STAT3 activation. By targeting FOSL1 mRNA for degradation via the RNA interference (RNAi) pathway, siRNA FOSL1 reduces the expression of GSC markers such as CD133 and decreases ALDH1 enzymatic activity, thereby inhibiting the self-renewal and tumorigenic potential of glioblastoma cells. It is primarily used as a research tool to investigate the TRPM7/STAT3/FOSL1 signaling axis in glioma progression.
- Other names
- FOSL1 siRNAFOSL-1 siRNAFOSL 1 siRNAsmall interfering RNA targeting FOSL1
02
Targets
FOSL1 (FOS-like antigen 1)
Beyond the preview
Go deeper on siRNA FOSL1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA FOSL1.